Trellus Health (TRLS) Share Price, News & Analysis

Company Overview

Trellus Health (AIM: TRLS) is a health services company providing value-based innovative solutions and services for chronic condition management that prioritises improved outcomes and member experiences while managing costs of care. Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate™, a whole-person technology-enhanced experience that meets each individual's unique needs and empowers them to master their physical and emotional health. Trellus Elevate's™ clinically proven solutions result in relieving disease burden, building self-management skills and promoting positive health behaviours that improve outcomes and enables thriving in the face of a chronic condition. The Company's proven whole person approach recognises the interconnectedness of various aspects of a person's life and aims to address the whole spectrum of factors that influence behaviour, to promote comprehensive well-being and human flourishing in a way that aligns with value-based care. Trellus Health's approach enables better health outcomes in a member-centric, personalised and comprehensive holistic solution. The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years. The Company is initially focusing on chronic costly GI conditions that have high mental health burden, such as inflammatory bowel disease ("IBD") which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis. Given the common emotional and mental health struggles often experienced by individuals suffering from a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions. The Trellus Elevate™ program incorporates the GRITT™ methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than seven years. This proprietary, resilience-driven methodology has been scientifically validated to demonstrate meaningful improvements in patient outcomes, 71% reduction in Emergency Department (A&E) visits, and 94% reduction in unplanned hospitalisations, which the directors of the Company believe indicates the potential for significant cost savings for healthcare payers and health systems. Patients with IBD managed with the proprietary resilience methodology also experienced a 49% reduction in required opioid use and a 73% reduction in corticosteroid use 12 months following starting the program which is a major indicator of improved health outcomes(1). Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information on Trellus Health, visit: www.trellushealth.com (1) Source: https://www.sciencedirect.com/science/article/pii/S1542356521012258

Key Stats

• Today's Range: 0.12 to 0.12
• 50-Day Range: 0.12 to 0.55
• 52-Week Range: 0.10 to 2.34
• Volume: N/A
• Average Volume: 12.81 million shs
• Market Capitalization: £516.14 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: LON:TRLS
• CIK: N/A
• Web: www.trellushealth.com
• Phone: 800-866-4165
• Fax: N/A
• Employees: 31
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (5)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£7.98 million
• Net Margins: -1,918.66%
• Pretax Margin: N/A
• Return on Equity: -67.29%
• Return on Assets: -22.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.63
• Quick Ratio: 17.11

Sales & Book Value

• Annual Sales: £359 thousand
• Price / Sales: 1.44
• Cash Flow: GBX 0.16 per share
• Price / Cash Flow: 0.76
• Book Value: GBX 9.67 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 430,119,000
• Free Float: N/A
• Market Cap: £516.14 thousand
• Optionable: Not Optionable
• Beta: 2.51